- Home
- UBS vs PFE Comparison
UBS vs PFE Comparison
Compare UBS & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UBS | PFE |
|---|---|---|
| Founded | 1862 | 1849 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.8B | 147.6B |
| IPO Year | 2014 | 2013 |
Fundamental Metrics
Financial Performance| Metric | UBS | PFE |
|---|---|---|
| Price | $54.91 | $27.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 14 |
| Target Price | ★ $60.30 | $29.29 |
| AVG Volume (30 Days) | 1.5M | ★ 31.8M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | 1.29% | ★ 6.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $62,579,000,000.00 |
| Revenue This Year | $7.40 | N/A |
| Revenue Next Year | $2.83 | N/A |
| P/E Ratio | ★ $17.22 | $65.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.30 | $23.59 |
| 52 Week High | $55.15 | $28.75 |
Technical Indicators
Market Signals| Indicator | UBS | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 62.70 | 64.17 |
| Support Level | $51.39 | $24.90 |
| Resistance Level | $55.15 | $28.75 |
| Average True Range (ATR) | 0.55 | 0.49 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 88.92 | 75.00 |
Price Performance
Historical ComparisonAbout UBS UBS Group AG Registered
UBS is a global financial institution built around its core strength in wealth management, serving high and ultra-high-net-worth individuals. In Switzerland, it also operates as a traditional retail and commercial bank. Its investment bank and asset management divisions complement the wealth business, providing tailored solutions to UBS clients while serving third-party customers by leveraging UBS' global reach and expertise.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.